OVERVIEW OF THE CLINICAL TRANSLATIONAL CORE AND IMPORTANCE OF THE CORE TO THE RESEARCH EFFORT We have identified the critical requirement to have a clinical translational core within the CCNE to coordinate application of our nanotechnologies to patient blood samples already collected and archived by other efforts. This core was not part of the original CCNE, but as we have started to apply our technologies to clinical specimens we feel it is an important core going forward in our renewal. For both blood protein biomarker and circulating tumor cell studies, the goal of this core is to utilize specimens already collected and prospectively being collected by other efforts (e.g., NCI ICMIC P50) in a systematic fashion with our nano-sensors being developed in RP2 and RP3. In addition, for the in vivo molecular imaging studies (endoscopic Raman imaging, photoacoustic molecular imaging) the goal of this core is to work with the NCI nanocharacterization labs and the Food and Drug Administration (FDA) in order to translate our nanoparticles into future clinical molecular imaging trials. Note, it is not the purpose of this core to actually collect samples from patients or to perform clinical trials, but just to facilitate clinical translation of nanotechnologies developed in the CCNE. Note also that the CCNE mechanism does not allow funding for prospective clinical trials, but by having this core we can bridge to other funded activities as well as apply for new funding for our clinical trials, to which we are whole-heartedly committed. In addition, the Canary Foundation is providing significant funding (in excess of $3IVI) for clinical trials for early cancer detection and providing partial funding for this and other cores (see Appendix 1 and letter of support).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Pu, Kanyi; Shuhendler, Adam J; Valta, Maija P et al. (2014) Phosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell tracking. Adv Healthc Mater 3:1292-8
Hudak, Carolyn S; Gulyaeva, Olga; Wang, Yuhui et al. (2014) Pref-1 marks very early mesenchymal precursors required for adipose tissue development and expansion. Cell Rep 8:678-87
Cheng, Kai; Kothapalli, Sri-Rajasekhar; Liu, Hongguang et al. (2014) Construction and validation of nano gold tripods for molecular imaging of living subjects. J Am Chem Soc 136:3560-71
Zhang, Mingliang; Bechstein, Daniel J B; Wilson, Robert J et al. (2014) Wafer-scale synthesis of monodisperse synthetic magnetic multilayer nanorods. Nano Lett 14:333-8
Sinclair, Robert; Kempen, Paul Joseph; Chin, Richard et al. (2014) The Stanford Nanocharacterization Laboratory (SNL) and Recent Applications of an Aberration-Corrected Environmental Transmission Electron Microscope. Adv Eng Mater 16:476-481
Dimov, Ivan K; Lu, Rong; Lee, Eric P et al. (2014) Discriminating cellular heterogeneity using microwell-based RNA cytometry. Nat Commun 5:3451
Pu, Kanyi; Shuhendler, Adam J; Jokerst, Jesse V et al. (2014) Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice. Nat Nanotechnol 9:233-9
Sasportas, Laura Sarah; Gambhir, Sanjiv Sam (2014) Imaging circulating tumor cells in freely moving awake small animals using a miniaturized intravital microscope. PLoS One 9:e86759
Park, Seung-Min; Sabour, Andrew F; Son, Jun Ho et al. (2014) Toward integrated molecular diagnostic system (i MDx): principles and applications. IEEE Trans Biomed Eng 61:1506-21
Wang, Jianbin; Quake, Stephen R (2014) RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A 111:13157-62

Showing the most recent 10 out of 57 publications